Alnylam Pharmaceuticals Inc Stock Price, News & Analysis

Alnylam Pharmaceuticals (Nasdaq: ALNY) will disclose its financial results for Q1 2023 on May 4, 2023, before U.S. markets open. A conference call to discuss the results and future expectations will take place at 8:30 am ET on the same day. Participants must register in advance to join the call. The company emphasizes its commitment to RNA interference (RNAi) therapeutics, marking a significant innovation in medicine for rare and common diseases. Alnylam’s product line includes ONPATTRO, GIVLAARI, and others, alongside a robust pipeline of investigational therapies. The firm aims to deliver transformative medications and continues to strengthen its position in the biotech sector.

On March 9, 2023, Alnylam Pharmaceuticals (Nasdaq: ALNY) and Medison Pharma announced an expansion of their partnership to include a multi-regional agreement covering Poland, Czech Republic, Hungary, Slovakia, Lithuania, Estonia, Latvia, and Israel. This agreement aims to enhance the commercialization of Alnylam's RNA interference (RNAi) therapeutics, including ONPATTRO®, GIVLAARI®, and OXLUMO®. GIVLAARI® and OXLUMO® have already received reimbursement approval in Poland. The collaboration is expected to improve patient access to innovative therapies in Central and Eastern Europe, reflecting a commitment to addressing unmet medical needs in these regions.

Alnylam Pharmaceuticals (Nasdaq: ALNY) has announced the appointment of Peter Kellogg to its Board of Directors. This move is seen as pivotal as the company aims to advance its P⁵x25 strategy and enhance its commercial performance. Kellogg brings extensive experience from top biopharmaceutical companies, including Biogen, Merck, and Celgene, where he played a crucial role in financial operations and corporate strategy. His expertise is anticipated to bolster Alnylam’s efforts in developing RNA interference therapeutics aimed at addressing unmet medical needs.

Alnylam Pharmaceuticals (Nasdaq: ALNY) announced its participation in several upcoming healthcare conferences. Management will present at the Cowen 43rd Annual Health Care Conference on March 8, 2023, at 2:10 pm ET in Boston, the Oppenheimer 33rd Annual Healthcare Conference on March 15, 2023, at 1:20 pm ET virtually, the Barclays Global Healthcare Conference on March 16, 2023, at 8:00 am ET in Miami, and the Stifel 2023 CNS Days on March 29, 2023, at 9:30 am ET virtually. Live webcasts will be accessible on the Investors section of Alnylam's website, with replays available within 48 hours of each event.

Alnylam Pharmaceuticals reported a strong financial performance for Q4 and full year 2022, with global net product revenues reaching $262 million and $894 million, respectively, representing a 35% annual growth. The company submitted a supplemental New Drug Application for ONPATTRO® to treat cardiomyopathy associated with ATTR amyloidosis, which was accepted by the FDA. For 2023, Alnylam expects combined net product revenues of $1.2 billion to $1.285 billion. The company also saw increased patient uptake across its product portfolio, marking significant growth in commercial treatment of hATTR amyloidosis.

Alnylam Pharmaceuticals announced that the FDA accepted their supplemental New Drug Application (sNDA) for patisiran, which targets ATTR amyloidosis with cardiomyopathy, with a PDUFA date set for October 8, 2023. The FDA noted no review issues and plans to hold an advisory committee meeting regarding the application. The sNDA was supported by positive results from the APOLLO-B Phase 3 study, showing improved functional capacity and quality of life in patients. The adverse event profile remains consistent with previous trials. This acceptance signifies a major milestone for Alnylam in addressing the treatment needs for patients with this condition.

Alnylam Pharmaceuticals (Nasdaq: ALNY) will announce its financial results for Q4 and the year ending December 31, 2022, on February 23, 2023, before U.S. markets open. Management will discuss the results and future expectations during a conference call at 8:30 am ET on the same day, which can be accessed via registration online. Alnylam is recognized for pioneering RNA interference (RNAi) therapeutics with products like ONPATTRO, AMVUTTRA, and others, alongside a robust pipeline under its "Alnylam P5x25" strategy aimed at innovative treatments for various diseases. More information is available on their website.

Alnylam Pharmaceuticals reported preliminary global net product revenues of $894 million for 2022, marking a 35% year-over-year growth. The launch of AMVUTTRA significantly contributed to a 37% increase in total TTR revenue, with $122 million and $69 million from ONPATTRO and AMVUTTRA in Q4 2022. The company maintained a strong balance sheet with $2.2 billion in cash and investments. The CEO expressed optimism about achieving long-term commercial goals.